9 月 17 日,阿斯利康宣布,其皮下注射首创生物制剂Saphnelo(Anifrolumab,阿尼鲁单抗皮下注射剂)针对系统性红斑狼疮(SLE)患者 III 期 TULIP-SC 试验的预定中期分析达到主要终点。TULIP-SC 是一项3 期、多中心、跨国、随机、双盲、安慰剂对照研究,旨在评估在接受标准护理(SOC)治疗的中度至重度活动性自身抗体阳性 SLE 患者中,皮下注射Saphnelo与...
Source Link9 月 17 日,阿斯利康宣布,其皮下注射首创生物制剂Saphnelo(Anifrolumab,阿尼鲁单抗皮下注射剂)针对系统性红斑狼疮(SLE)患者 III 期 TULIP-SC 试验的预定中期分析达到主要终点。TULIP-SC 是一项3 期、多中心、跨国、随机、双盲、安慰剂对照研究,旨在评估在接受标准护理(SOC)治疗的中度至重度活动性自身抗体阳性 SLE 患者中,皮下注射Saphnelo与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.